BC Innovations | Jun 14, 2018
Translation in Brief

There’s more to MIF

In a May Science Translational Medicine study, a European-U.S. team has shown macrophage migration inhibitory factor or sCD74, a soluble form of one its receptors, could reduce the risk of acute kidney injury in cardiac...
BC Innovations | Jun 5, 2018
Distillery Therapeutics

Renal

INDICATION: Renal damage Patient sample, cell culture and mouse studies suggest MIF or its receptor CD74 could help treat ischemia/reperfusion-associated acute kidney injury (AKI). In serum samples from 60 cardiac bypass surgery patients who experienced...
BC Innovations | Oct 3, 2017
Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Patient sample and mouse studies suggest inhibiting MIF and DDT or their receptor CD74 could help treat progressive MS. In patients and healthy volunteers, genotyping identified associations between two polymorphisms in...
BC Week In Review | Aug 11, 2017
Company News

Sutro, Celgene revamping immuno-oncology deal

Sutro Biopharma Inc. (South San Francisco, Calif.) said it is refocusing a 2014 immuno-oncology multi-specific antibody and antibody-drug conjugate (ADC) deal with Celgene Corp. (NASDAQ:CELG). As part of the new agreement, the partners terminated Celgene's...
BC Extra | Aug 10, 2017
Company News

Sutro, Celgene revamping immuno-oncology deal

Sutro Biopharma Inc. (South San Francisco, Calif.) said it is refocusing a 2014 immuno-oncology multi-specific antibody and antibody-drug conjugate (ADC) deal with Celgene Corp. (NASDAQ:CELG). As part of the new agreement, the partners terminated Celgene's...
BC Week In Review | Sep 22, 2014
Company News

Seattle Genetics, Genmab deal

Seattle Genetics granted Genmab rights to use antibody-drug conjugate (ADC) technology with Genmab's cancer candidate HuMax-AXL-ADC , an ADC against AXL receptor tyrosine kinase (AXL; UFO). Genmab will receive $11 million up front and is eligible...
BC Week In Review | Apr 25, 2011
Company News

Genmab, Seattle Genetics deal

Seattle Genetics granted Genmab rights to use its antibody-drug conjugate (ADC) technology with Genmab's preclinical cancer candidate HuMax-CD74-ADC , an ADC against CD74 molecule major histocompatibility complex class II invariant chain . Genmab is responsible for preclinical...
BC Week In Review | Dec 13, 2010
Clinical News

Milatuzumab: Phase I/II data

An ongoing, open-label, dose-escalation, U.S. Phase I/II trial in 9 evaluable patients showed that milatuzumab in combination with veltuzumab produced 4 objective responses. Dose-escalation has reached 16 mg/kg milatuzumab with no dose-limiting toxicities reported. Patients...
BioCentury | Aug 2, 2010
Emerging Company Profile

Carolus: Targeting cytokines

While cytokines are known to be effective targets to treat autoimmune and inflammatory diseases, inhibiting these molecules can restrict the defensive functions of the immune system and increase a patient's susceptibility to infection. Carolus Therapeutics...
BC Week In Review | Jun 21, 2010
Clinical News

Milatuzumab-doxorubicin conjugate: Phase I/II started

Immunomedics began an open-label, U.S. Phase I/II trial to evaluate 4 dose levels of IV milatuzumab conjugated with doxorubicin for up to 8 cycles in groups of 3-6 patients. The company plans to enroll up...
Items per page:
1 - 10 of 11